You are here: Home » PTI Stories » National » News
Business Standard

USIBC urges govt to ease regulatory curbs on APIs, medical devices

Health Medical Pharma

Press Trust of India  |  New Delhi 

Amid coronavirus pandemic, a top American advocacy group has urged the Indian government to ease regulatory curbs to expedite production of active pharmaceutical ingredients, medical devices and other critical healthcare equipment.

US-India Business Council has written to Prime Minister Narendra Modi this week to suggested the Centre to "temporarily relax regulatory barriers that impede the quick production of Active Pharmaceutical Ingredients (APIs), medical devices, and other critical healthcare infrastructure and avoid the imposition of export restraints on these products".

India, the world's main supplier of generic drugs, earlier this month restricted export of 26 pharmaceutical ingredients and the medicines made from them, including Paracetamol - a common pain reliever also sold as acetaminophen, as the coronavirus outbreak plays havoc with supply chains.

It was unclear how the restriction would impact the availability of these medicines in the countries that import from India and also depend on China.

In the US, for instance, Indian imports accounted for 24 per cent of medicines and 31 per cent of medicine ingredients in 2018, according to the US Food and Drug Administration.

Besides, the USIBC also suggested setting up of a task force within the Ministry of Commerce, Invest India, or elsewhere in the government to coordinate with industry groups regarding the resources, essential goods and services and technical capabilities.

In the letter to the Prime Minister, it urged the government to focus on immediate and rapid-response requirements to ease doing business and ensure the viability of important supply chains, including continued relaxation and flexibility of work from home rules, and temporarily permit the importation of used computer equipment for home-based employees.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, March 29 2020. 14:12 IST